Blog

Blog

Indian Pharma Market2017 January Update - Slow Start to the New Financial Year

In April month, market clocked just single digit growth rate. This was on account of two factors.

Primary reason was that the trade (distributors) reduced their buying and keeping the inventory to bare minimum, due to uncertainity on account of imminent announcement of tax rates under GST. Stockists just didn’t want to be caught on the wrong foot and suffer any loses. However, this is going to be a short-term impact, as GST council in its next meeting on May 18-19 in Kashmir, will most likely announce the tax rates. This will end any uncertainity on account of this.

Second reason for the lower growth was shift to prescribing generics among certain section of the medical fraternity. At least, most of the government medical colleges and hospitals have started prescribing generics. The clarity on this issue may take little longer to come through.

Key Industry Highlights for April-17

  1. Market posted a 8.3% growth during the previous month, which was relatively higher than April-16 growth which was 5.5%. April growth was slower than that in March 17.
  2. Anti Infectives was virtually stagnant during previous month
  3. In chronic care, cardio segment posted single digit growth. CNS also grew in single digit. Though, Anti-Diabetic and Derma had double digit growth
  4. Growth Drivers for the previous months were - 3.4% due to volume, 1.7% due to price increase & 3.2% on account of new introductions.
  5. April quarter saw a volume growth of 3.4 % only and price growth was just 1.4%, which has been consistently going down
  6. Impact of FDCs

    a)     FDC segment de-grew by 18.4%, while non-FDC segment grew by 8.9%

    b)     Volumes are pulling down the growth for the FDCs.

    c)     In FDC segment, Indian companies de-grew by 7.8%, while for MNC de-growth was 39.2%

Major Highlights for Month of April-17

The market registered growth of 8.3 %, and clocked Rs. 9474 crore in the previous month

Corporate

  1. Amongst the top 10 Corporates, Sun had the highest growth at 11.3%, followed by Mankind at 11.2% and Lupin at 10.8%
  2. Glaxo showing signs of recovery by posting monthly growth of 10.1%
  3. 27 Corporates, amongst top 50 had faster growth than the overall growth, of which 24 Corporates had double digit growth
  4. Amongst the top 50 Corporates, Wockhardt had the highest growth of 24.3%, followed by Micro Labs at 19.8% and Himalaya at 19.3%
  5. Amongst the 11-20 ranked Corporates, Micro Labs had the highest growth at 19.8%, followed by Glenmark at 17.8% and Emcure at 16.9%
  6. Amongst the 21-30 ranked Corporates, Wockhardt had the highest growth at 24.3%, followed by Himalaya at 19.2% & Eris at 14%
  7. Amongst the 31-40 ranked Corporates, Indoco had 18% growth, followed by Franco at 14.8%, followed closely by Bharat Serum at 14.3%
  8. Amongst the 41-50 ranked Corporates, Fourtts grew at 21.6%, followed by Boehringer Ingelheim at 20.2% and Akumentis at 17.9%
  1. Amongst the 51-60 ranked Corporates, Centaur led at 51% followed by Corona at 34.6% and Biocon at 20.9 %
  2. Amongst the 61-70 ranked Corporates, Danone leads at 29.9%, and Pharmed at 10% and Hedge and Hedge at 6.4%
  3. Amongst the 71-80 ranked Corporates, Roche leads at 17.8%, followed by Shreya at 13.6% and Biologicals E at 8.7%
  4. Amongst the 81-90 ranked Corporates, Mylan grew at 42.7% followed by Koye at 27.2% and Med Manor at 16.6%
  5. Amongst the 91-100 ranked Corporates, Gland grew at 51.8 %, followed by Curatio at 22.6% and Ordain at 9%
  6. Amongst the 101-150. few of the fast growing Corporates include BMS, Piramal HC, Reliance LS, Indian Immunologicals, United Biotech, KLM Pharma, Vanguard, Icon, Strassenburg
  7. Amongst the 151–200, few of the fast growing Corporates include Torque Pharma, Seagull Lab, Innovcare, Bennet, Goddres Pharma, Srinivas Gujarat, Tasmed, Bharat Biotech

Companies

  1. Abbott HC grew at 1.1 %, whereas Abbott India grew at 11.1%
  2. Zuventus grew by 14.1%, Emcure at 18.6%, and Micro Labs by 20.4%
  3. Sun portfolio grew by 14.4%, whereas Ranbaxy portfolio grew at 6.1%

New Companies (launched within last 36 Months)

Total 47 companies have been launched in last 36 Months, of which 4 crossed Rs. 10 crore revenue

Indian V/s MNC

  1. Indian companies grew by 9.1 %, while the MNC grew by 5.2 %
  2. Amongst the top 50 in MNCs, Boehringer Ingelheim grew at 20.2% followed by AstraZeneca at 12.1% and Janssen which grew at 11.4%

NLEM, Non NLEM & Non-Scheduled Para 19 market

  1. The NLEM 2013 molecules segment de-grew by 5.3% whereas the non-NLEM segment grew by 10.4% resulting in an overall growth of 8.3%
  2. NLEM & Non-NLEM segments had 3.4% and 1.4 % unit growth respectively.

Therapy

  1. 10 therapies grew faster than the market
  2. Respiratory grew at 5.3%, Gastrointestinal grew at 7.6 %, Pain & Analgesics grew at 7.5% and Anti Infectives had a negligible growth of 0.6%
  3. In chronic care, Anti-diabetic grew at 17.8%, Cardiac at 8.7 %, and Neuro/CNS at 5.4%
  4. Anti-Malarial de-grew at 16.6%, while VMS grew at 5.1%
  5. Derma had 13.9% growth rate

Regional Dynamics

  1. 14 regions grew faster than the overall market
  2. Jharkhand grew fastest at 21.6%, followed by North Karnataka at 20.47% & South Rajasthan at 20.36%
  3. 5 regions had negative growth

Molecules

  1. Amoxycillin + Clavulanic Acid decline stopped, while Glimepiride + Metformin grew at 20.71%
  2. Glimepiride + Metformin was pegged at Rs. 175.26 crore, while Amoxycillin + Clavulanic Acid was  pegged at Rs. 129.22 crore
  3. Teneligliptin total segment is now worth Rs. 430 crore on MAT basis
  4. Azilsartan is now valued at Rs. 14 crore, Sofosbuvir & combinations valued at Rs. 468 crore & Ltraconazole valued at Rs. 441 crore
  5. Paracetamol grew at 6.6%, plain Atorvastatin at -9.6%, Probiotic Microbes at 27.7%, Pantoprazole plain declined by 10.9%, Montelukast + Levocetrizine at 11.4%, Vitamin-D at 4.7%, Hydroquinone + Mometasone + Tretinoin at 8.15%, Voglibose + Metformin + Glimepiride at 86.4%, Protein Supplements at 39.2%, Plain Azithromycin declining at 19.1%, Calcium Carbonate + Vit D3 at 27%

Brands

  1. Mixtard lead with Rs. 42 crore, followed by Glycomet GP at Rs. 40 crore, Spasmoproxyvon Plus at Rs. 37 crore, Lantus at Rs. 32 crore, Galvus Met at Rs. 33 crore and Liv 52 and Janumet at Rs. 30 crore
  2. Few Brands which gained ranks on MAT basis include Bortenat(+60), Hepcinat LP(+325), Combiflam(+7), Cilacar(+40), Udiliv(+31), Revital H(+26), Ultracet(+9), Duolin(+32), Gluconorm G (+21), Telma H(+6), Allegra(+22), Synflorix(+5), Gemer(+18), Ecosprin AV(+26), Novomix(+13), Ascoril Plus(+12), Duphaston(+12), Jalra M(+5).
  3. Ascoril LS from Glenmark was ranked 300th on MAT basis

Recent New Launch Molecule Performance

  1. Azilsartan is a recently launched molecule now valued at Rs. 14 crore on MAT Basis with Zilarbi (Emcure) leading followed by Azildac (Zydus) and Aztric (Intas)
  2. Two new brands of Luliconazole were launched by Lupin and Ethinext pharma. Luliconazole segment is worth Rs. 90 crore on MAT basis
  3. Benidipine molecule is now valued at Rs. 4 crore on MAT basis with Benipack (Koye) leading followed by Inzit (Eris) and Benitowa (Akumentis)
  4. Acotiamide is now valued at Rs. 24 crore on MAT basis with Acogut (Lupin) leading, followed by Actapro (Sun) & Acotrust (DRL)
  5. Dulaglutide launched under the brand name Trulicity by Eli Lilly, and now valued at Rs. 6 crore.

New Launches in April-17

  1. Total 249 brands & 453 SKUs were launched
  2. Top 5 new brands for April 2017 are Easy Six, IWIN, Provict Ml, NISTAMI, and Prohance
  3. Novartis launched Vymada in Sacubitril + Valsartan segment
  4. Azilsartan is launched by more 4 companies.
  5. Within Antidiabetic, 9 new brands were launched
  6. Within the VMS category, B29 fast (Corona), FOL 123 (Pharmed) were new brands
  7. Within Cardiac, 27 new brands were launched
  8. Within Derma, 16 new brands were launched, few were Itchguard Plus (Reckitt), Zinikam  (Curatio), Bioscalin (Unichem)
  9. Within Gastro, 18 new brands were launched
 
Comment 4
 
Name *
 
Email ID *
 
Comment
 
 
 
 
Recent Blog Posts
arrow Thailand’s hospital sector commands much more value than India
arrow Over USD3B of PE commitment for May’19
arrow Destroying credibility of The Economic Times
arrow April’19 Score: China – 18, India – 0
arrow Is threat to offline retail in consumer electronics from e-commerce overhyped?
arrow Chinese pharma companies on in-licensing spree
arrow Healthcare sector drew USD24B+ of PE investment in 2018
arrow Indian Pharma Domestic Formulation - March Update
arrow Indian Pharma Domestic Formulation - February Update
arrow Indian Pharma Domestic Formulation - January Update
arrow Can Byju’s go the way of Educomp and other Digital Classroom companies?
arrow Indian Pharma Domestic Formulation - November Update
arrow Early stage and MSME funding witnesses subdued action in November 2018
arrow Indian Pharma Domestic Formulation September Update
arrow USD 2.7 B of private equity investment and 24 SME IPOs in Sep’18
arrow 2018 Award for India’s Most Pusillanimous Company Board
arrow FMCG valuations have peaked, says report by Jeffreys
arrow Long way to go for Indian construction companies
arrow Wholesale dependence high in FMCG space
arrow Fintech is hot globally, headed for a record year
arrow CCI penalises Glenmark & 2 more pharma companies in distribution case
arrow RBI Report on State Finances for FY17-18 shows slippages
arrow USD 1.85 B of VC/PE investment reported in Global Healthcare space in Jun’18
arrow USD 1.1 B of private equity investment reported in Jun’18 in India
arrow USD 2.3 B of private equity investment reported in May’18 in India
arrow USD 2.2 B of private equity investment reported in Apr’18 in India
arrow China emerging as the R&D leader in oncology biotech?
arrow USD 1.9 B of private equity investment reported in Mar’18 in India
arrow FDCs issue moving further, CDSCO committee calls stakeholders for data
arrow DTAB recommends prescription switch by pharmacies / chemists
arrow Indian Pharma Market Feb'18 Update - Steady Growth Continues
arrow USD 1 B of private equity investment reported in Feb’18 in India
arrow Indian Domestic Pharma January'18 Update - Upward Growth March Continues
arrow USD 2.3B of private equity investment reported in Jan’18 in India
arrow Global Healthcare PE Deals Tracker - January 2018 Update
arrow Apollo group well on its way to creating a pharma distribution behemoth
arrow USD 864m of private equity investment reported in Dec’17
arrow Global Healthcare PE Deals Tracker - December'17 Update
arrow Indian Pharma Market Dec'17 Update - Growth remains steady at 7.8%
arrow Indian Pharma Market Nov'17 Update - Growth inching up, touches 8.1%
arrow Strong brands equals supernormal profits, shows MDH
arrow Indian Pharma Market Oct'17 Update - Growth inching up, touches 6.5%
arrow USD 1.2B of deals in global healthcare space in Oct'17
arrow USD 1380m of private equity investment reported in Oct’17
arrow Spurious RTI data – 40% vacancy in Mum-Ahd trains
arrow RBI’ Revenge
arrow Tax Collections in India – A primer
arrow Ratan Tata is right – very few disruptive startups get funded
arrow USD 782m of private equity investment reported in Sep’17
arrow VC/PE investments hit a high in Aug 2017
arrow VC/PE investments cross USD1B in Jul’17
arrow VC/PE investment headed for a big year at half way mark
arrow Sharp reduction in the inventory days
arrow Indian Pharma Market May'17 Update - growth further slows down further, down to just over 7%
arrow A strong move by the new USFDA Head to shorten generic approvals timelines
arrow No more approval for new drugs by the state FDAs
arrow Another month of >USD1B reported investment
arrow Imminent ‘generics-isation’ of the Indian pharma – a blessing in disguise
arrow Indian Pharma Market2017 January Update - Slow Start to the New Financial Year
arrow Indian handicraft exports are booming
arrow Robust inflows continue in VC/PE deal space
arrow Will Electric Vehicles replace normal vehicles?
arrow What Young Think?
arrow Mobile subscriber base at 895 million, up by increased by 5.68 million in March
arrow Government to launch 3 year plans
arrow H1B – No legislative changes as yet!
arrow India retains its place as the fastest growing economy in the World
arrow Vacancies are rampant!
arrow Focus on improving Ease of Doing Business within India
arrow Controlling Population Growth
arrow Digital Payments is the Way
arrow Exports and Imports Increase in March
arrow Controlling Food Wastage
arrow 5G is Here!
arrow Economic data turns adverse
arrow Salaries in India
arrow RBI expects higher inflation
arrow Jio is shaking up the telecom industry
arrow Weather related industries sees Spike in Sales
arrow Manufacturing picking up as March data shows
arrow Water availability numbers in India make for shocking reading
arrow India needs to tap its tourism potential better
arrow Mar’17 sees smart revival in VC/PE deal space
arrow Software as a Service business has come a long way in India
arrow GST is becoming a reality – Advantages of GST
arrow Making India a manufacturing powerhouse
arrow People are worried around the globe
arrow Startup Fund will change Indian Entrepreneurship
arrow Farm Loan Waiver – A Bad Idea?
arrow Smart Cities – Not Taking Off as Yet
arrow Trends in Technology
arrow Nordic nations are the world's happiest
arrow Vodafone Idea Merger to create largest Telecom company in India
arrow Genomic Research – a new Sunrise Industry?
arrow Currency levels reach 70% of pre-demonetisation levels
arrow New National Health Policy unvieled
arrow Reforms in financial sector expected
arrow Rising inflation will prevent rate cuts by RBI
arrow Solar Power prices hit a new low
arrow UP Election Victory may drive Reforms
arrow Rich in India - the Hurun List
arrow Japanese funds are investing in Indian Startups
arrow India Inc and the new normal in CEO salary
arrow Giving in India
arrow Startup India - a good start
arrow Hubtown loses case, now what about Tata Docomo?
arrow Israel – the startup haven
arrow Crowdfunding is huge
arrow The problem of NPA
arrow Corporates are paying attention to CSR
arrow Note ban: Impact on Economy
arrow Time to reboot for Indian IT
arrow India is making rapid strides in Space busines
arrow E-Retailing losses – Any lessons?
arrow Indian Pharma Market2017 January Update - Double Digit Growth Continues
arrow Crisis in Infosys
arrow Henry Schein: A remarkable growth story
arrow Angel investing in public markets
arrow Jan’17 sees tepid VC/PE activity
arrow Why is Divi’s stock price falling?
arrow Dec'16 witnesses USD2.4B of VC/PE investment
arrow Indian Market December 2016 Update - Anti-Diabetic and Cardiac comes to the rescue of the overall ma
arrow Indian Pharma Market - Novemeber Update
arrow India emerges tops in JBIC FDI survey for 2016
arrow VC/PE deal space back to pedestrian pace in Nov’16
arrow Demonetisation to have several long term benefits for India
arrow Oct’16 sees improvement in VC/PE deal space
arrow Indian Pharma Market September 2016 Update - Double Digit Growth Continues
arrow August sees better deal traction in private space
arrow FMCG companies hope for revival in rural demand
arrow VC/PE investments crater in June
arrow Expanding distribution helps Marico beat GDP growth
arrow Indian Pharma Market May 2016 Update - Growth improves, but still in single digit
arrow Future Consumer – as confused as ever
arrow Valuation of a few ecomm companies
arrow VC/PE investments slip again in May
arrow QSR companies continue to struggle for growth
arrow Apr’16 witnesses rebound in VC/PE deal amounts
arrow DS Group’s candy Pulse makes electrifying launch
arrow Consolidated impact of three key policy decisions on the pharma market - 4.5% of the overall market
arrow Mar’16 witnesses ~USD 504m of VC/PE investments
arrow Impact of the banning of nearly 350 FDCs by the government last week
arrow Indian Pharma Market - February 2016 update: steady growth continues
arrow Agree with Murthy, ‘delivery food tech’ is not a business
arrow Jan’16 starts with USD 800m of VC/PE investments
arrow Indian Pharma Market - January 2016 update: steady growth continues
arrow Indian Pharma Market December 2015 Update - steady double digit growth continues
arrow Indian Pharma Market - November Update
arrow Indian Pharma Market - October Update: a blockbuster month
arrow VC/PE investments for 2015 close at USD 14B
arrow USD 1.27B of VC/PE transactions in November’15
arrow Winner takes all in tech and e-commerce
arrow VC/PE investments USD 12B for Jan-Oct-15
arrow The thuggery of AIOCD needs to be stopped
arrow Indian Pharma Market - September Update: relatively slower month
arrow Quality of accounting at Pharma companies going down
arrow Monthly VC/PE deal count touches all time high in Sep’15
arrow India has the most US FDA approved API plants in the world
arrow Vaccine companies are raking it in
arrow India most profitable pharma company is…Serum Institute
arrow The great Indian infra asset sale
arrow Indian pharma needs a period of valuation consolidation
arrow Indian Pharma Market August 2015 Update - double digit growth continues
arrow Is Sun Pharma losing the plot?
arrow USD 1.3b of private equity investments in Aug’15
arrow Government VC fund to support pharma R&D
arrow Cipla’s consumer health business to roll from FY17
arrow PE exits at all-time high in 2015
arrow MSO numbers expected to surge with DAS Phase-III coming up
arrow Annual Capacity Addition Targets for Solar Power set
arrow India best performing emerging market so far
arrow Indian Pharma Market July 2015 Update - double digit growth continues
arrow July’15 sees 91 VC/PE deals aggregating ~USD 1.7b
arrow Modern Dental Lab files for IPO
arrow Syngene business better than Biocon?
arrow Regulation does not pose a hurdle for online pharma
arrow Indian Pharma Market June 2015 Update
arrow More banks launching m-wallets
arrow June’15 sees 65 VC/PE deals
arrow Innovation and The lowest BRIC
arrow Indian Pharma Market April 2015 Update
arrow VC/PE sector headed for a big year
arrow LED market to grow at 40% plus
arrow Zydus planning a big acquisition?
arrow Indian Pharma Market March 2015 Update
arrow Zydus group announces big investment in hospitals
arrow Mar’15 sees 57 VC/PE deals aggregating USD735m
arrow Banks commit to funding 60,000MW of renewable energy
arrow Can change in packaging raise sales by 50%?
arrow Adlabs IPO focusses attention on Indian Amusement park business
arrow Indian Pharma Market February 2015 Update
arrow ITC targets Rs 1 trillion turnover from FMCG
arrow 53 VC/PE transactions recorded in Feb’15
arrow India’s chocolate market crosses Rs 100B mark
arrow Indian snack food market growing at 25% CAGR
arrow Haldiram’s combined revenues is Rs 3500 crore!
arrow Auto sales growth muted in January
arrow Jan’15 sees $1.4 billion of venture capital investment
arrow Autopart retail a very profitable business in the US
arrow Indian Pharma – Likely Future Trends
arrow Indian Pharma Market December 2014 Update
arrow Car Care an attractive business
arrow Oil price headed to $20 a barrel?
arrow 3M’s car detailing business now Rs 175 crore annually
arrow BRIC to IC
arrow Deal count up sharply in 2014
arrow India patent data proves critics wrong
arrow Impact of Rouble depreciation on the Indian pharma industry
arrow Spice 20% market share up for graps
arrow Indian Pharma Market November 2014 Update
arrow Shocking practices of Indian pharma
arrow InMobi not quite the investor darling now?
arrow Will India pharma look more closely at US nutra market?
arrow Jubilant Foodworks continues to face adverse demand environment
arrow Brokers hot on agrochem sector
arrow Samsung now India’s second largest consumer company
arrow Flipkart posted Rs 28bn revenue in FY14
arrow Apple revenues up 10x in 4 years in India
arrow Honda Motorcycle catching up with Bajaj Auto in motorcycle market
arrow 100 mid market hotels on sale
arrow Hardcastle plans to more than double outlets in 3-5 years
arrow Flipkart Big Billion Day: Beginning of the end for Flipkart?
arrow NPPA Loses Pricing Power
arrow Another online doctor appointment site gets funded
arrow Online ad market in India to reach Rs 3,575 cr by FY15
arrow Sutlej planning big expansion in home textiles
arrow Biyani claims food park is necessary for food business
arrow The outdated moped still clocks big numbers!
arrow Brick and mortar furniture chains scaling back
arrow Startups creating new categories in processed foods
arrow Pro Kabaddi was a big hit
arrow Market excited by Cipla’s combination inhaler launch
arrow Dental care chain MyDentist raising funds again
arrow Wholesalers take to sourcing from e-commerce sites
arrow Massive housing supply glut in Mumbai
arrow Britannia aims to take leadership from Parle in biscuits
arrow Indian Pharma Market July 2014 Update
arrow Arvind Mills aims to double turnover in 4 years
arrow Logistics Stocks give super returns
arrow Dai Ichi rises 15% today, hits new all time high!
arrow Bullish on Chemical Sector
arrow Godrej Appliances expects to grow 30%
arrow 10th July order of NPPA on price control
arrow DRL is sharply hiking R&D spends
arrow Why did Congress lose so badly? Simple answer – the voter knows
arrow Connexios Deal with Boeringher Ingelheim
arrow Yum! Brands to triple store count
arrow CPVC: A rapidly growing market
arrow Kotak PE set for bumper returns in Indus Biotech
arrow Mobile data usage surging
arrow India’s toothpaste market witnessing strong competitive activity
arrow Dabur still reporting volume growth in teens
arrow Operational costs galloping for Domino’s?
arrow Indian Pharma Market - January 2014 Update
arrow India's per capita footwear consumption is ~2 pairs
arrow TVS is outperforming for a change
arrow Titan reaches 100+ towns now
arrow Slowdown at V-Guard
arrow Indian Pharma Market - December 2013 Update
arrow Cadila set for sharp growth in US markets
arrow We remain bearish on economic scenario
arrow Car sales end negative for 2013
arrow Rural consumer taking to packaged fruit juice
arrow Adhesives market in India
arrow Retailers report worst festive sales in 10 years - Mint
arrow Festive season missing the retail spark this time
arrow 2 wheeler market to grow in single digits henceforth?
arrow Innerwear market continues it hot streak
arrow Has Crisil got its QSR numbers wrong?
arrow Goldman remains hyper bullish on Jubilant Food
arrow Why we think organised tyre retail is a good business
arrow Impact of ceiling price on drugs (270 drugs)
arrow Indian Pharma Market - July Update
arrow MyTVS is the leader in multibrand car servicing
arrow Growth grounds to a halt for Jubilant Foods
arrow Dental demand in India varies strongly with per capita income
arrow Finolex Cables wants to do a Havells
arrow HUL has 3 new Rs 10bn brands
arrow A monkey would have made money in stocks in 2012
arrow Angel Broking puts a Buy on TTK Healthcare
arrow Fabric wash market currently at $2.8bn, a mature market
arrow Distribution emerging as a key factor in FMCG, says report
arrow Life gets tougher for food chains as consumers reduce spends
arrow Growth March of Indian Pharma Market Continues
arrow Deepening consumer gloom
arrow Ikea’s nod a great positive for India
arrow Currently there is potential for 2453 Domino’s outlets, says Goldman Sachs
arrow Institutional brokers highly bullish on Jubilant Foodworks (JFL)
arrow Lavazza looking to exit Barista, says The Economic Times
arrow Café Coffee Day still to get profitability right
arrow Jubilant Foodworks Q2 results, 42% yoy revenue growth
arrow McDonald’s needs to get its act together in India
arrow Government plans a crackdown on pharma firms selling drugs as dietary supplements